Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer Inks Deal With GlycoMimetics

by Ann M. Thayer
October 16, 2011 | A version of this story appeared in Volume 89, Issue 42

Pfizer has licensed GlycoMimetics’ GMI-1070 molecule, which FDA has designated an orphan drug and given fast-track status. Based in Gaithersburg, Md., GlycoMimetics is testing the rationally designed selectin antagonist as a treatment for vaso-occlusive crisis, or restricted blood flow to organs, associated with sickle cell disease. Although the genetic and molecular causes of sickle cell disease have been known for decades, therapy for the painful crises has not significantly advanced, according to the companies. After GlycoMimetics completes a Phase II trial now under way, Pfizer will take over further development and commercialization and pay as much as $340 million, including an up-front fee and milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.